Citius Pharmaceuticals, Inc. (CTXR)

NCM – Цена в реальном времени. Валюта: USD

0.76

+0.04 (5.40%)

Рынок открыт: Aug 12, 2026, 2:08 PM EDT

0.71

-0.01 (-1.39%)

Предыдущая сессия: Aug 11, 2026, 7:47 PM EDT

12.08.2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D.

05.08.2026

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., Aug. 5, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority U.S. treatment centers, and other key indicators supporting the product's commercial launch.

Видео

No Data

There is no data to display

Пресс-релизы

12.08.2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

05.08.2026

Citius Pharmaceuticals, Inc. (CTXR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Citius Pharmaceuticals, Inc. (CTXR)

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Видео

No Data

Пресс-релизы

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Видео

No Data

Пресс-релизы

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Search stocks

Citius Pharmaceuticals, Inc. (CTXR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Citius Pharmaceuticals, Inc. (CTXR)

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Видео

No Data

Пресс-релизы

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Видео

No Data

Пресс-релизы

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment